-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|February 21, 2025

Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

Author(s)Ryan Haumschild, PharmD, MS, MBA, CPEL, Matthew Davids, MD, MMSc

Panelists discuss how patient-reported outcomes and real-world evidence influence clinical decision-making when selecting Bruton tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

Episodes in this series

EP. 1 Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP. 1 Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP. 2 Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP. 2 Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP. 3 Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP. 3 Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP. 4 Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP. 4 Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP. 5 Future Directions and Research Priorities in BTKi Treatment Approaches

EP. 5 Future Directions and Research Priorities in BTKi Treatment Approaches

EP. 6 Latest Trends and Innovations in CLL and MCL Treatment

EP. 6 Latest Trends and Innovations in CLL and MCL Treatment

EP. 7 CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 7 CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 8 Navigating CLL Treatment Choices

EP. 8 Navigating CLL Treatment Choices

EP. 9 Therapy Sequencing in CLL

EP. 9 Therapy Sequencing in CLL

EP. 10 MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 10 MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 11 MCL Therapy Selection and Sequencing

EP. 11 MCL Therapy Selection and Sequencing

EP. 12 Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

EP. 12 Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

EP. 13 Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

EP. 13 Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

EP. 14 Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL

EP. 14 Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL

EP. 15 Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences

EP. 15 Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences

EP. 16 Implementation of Shared Decision-Making in BTK Inhibitor Treatment

EP. 16 Implementation of Shared Decision-Making in BTK Inhibitor Treatment

EP. 17 Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence

EP. 17 Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence

EP. 18 Future Directions and Overcoming Challenges in BTK Inhibitor Therapy

EP. 18 Future Directions and Overcoming Challenges in BTK Inhibitor Therapy

EP. 19 Impact of Access Challenges on Patient Outcomes in CLL and MCL Care

EP. 19 Impact of Access Challenges on Patient Outcomes in CLL and MCL Care

EP. 20 Balancing Clinical Benefits and Costs of BTK Inhibitors

EP. 20 Balancing Clinical Benefits and Costs of BTK Inhibitors

EP. 21 Inflation Reduction Act: Impact on Health Care Systems’ Utilization of BTK Inhibitors

EP. 21 Inflation Reduction Act: Impact on Health Care Systems’ Utilization of BTK Inhibitors

EP. 22 Inflation Reduction Act: Impact on Affordability of BTK Inhibitors

EP. 22 Inflation Reduction Act: Impact on Affordability of BTK Inhibitors

EP. 23 Inflation Reduction Act: Impact on Clinical Pathways for BTK Inhibitors

EP. 23 Inflation Reduction Act: Impact on Clinical Pathways for BTK Inhibitors

EP. 24 Inflation Reduction Act: Clinical Challenges

EP. 24 Inflation Reduction Act: Clinical Challenges

EP. 25 Payer Policies and Access Strategies

EP. 25 Payer Policies and Access Strategies

EP. 26 Strategies for Managing Costs of Long-Term BTK Inhibitor Therapy

EP. 26 Strategies for Managing Costs of Long-Term BTK Inhibitor Therapy

EP. 27 The Future of BTK Inhibitor Therapies in CLL and MCL

EP. 27 The Future of BTK Inhibitor Therapies in CLL and MCL

How do patient-reported outcomes and real-world evidence influence your clinical decision-making process when selecting BTK inhibitor therapies for CLL and MCL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Experts featured in this series.

The Right Fit First: How Psychiatrists Approach Initial Treatment and Patient Adherence

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Experts featured in this series.

Formulary Frustrations: How Insurance Constraints Shape Psychiatric Treatment Decisions

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver Support

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

The 5-Year Horizon: Evolving Paradigms in Ischemic Stroke Management

ByMark Makhinson, PharmD, MBA,Andrew Russman, DO, FAHA, FAAN,Danison Emmerson, MD,David Z. Rose, MD

June 22nd 2026

Closing the Gap: Underrecognition and the Critical Need for Early Diagnosis in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS